Editorial Board


  • Pierre Blanchard, MD, PhD, Gustave Roussy, Villejuif, France, Radiation oncology,  urologic oncology,  prostate cancer,  biostatistics,  head and neck cancer
  • Daniel Zips, MD, Charité,, Department of Radiation Oncology, Berlin, Germany, MR LINAC image-guided radiotherapy, high-precision radiotherapy, stereotactic radiotherapy and 4D radiotherapy, novel combination treatments, hyperthermia cancer treatment, re-irradiation, clinical trials

Associate Editors

  • Pierfrancesco Franco, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, Clinical Oncology, focusing on gastrointestinal malignancies, head and neck and breast cancer
  • Joanna Kazmierska, MD, PhD, Greater Poland Cancer Centre, Poznan, Poland, multidisciplinary treatment of head and neck cancer,  prognostic and predictive factors for both tumour response and treatment toxicity,  including PROMs,  application of AI methods such as radiomics in radiotherapy,  optimizing clinical data collection for research purposes
  • Hina Saeed, MD, Lynn Cancer Institute – Baptist Health City, Boca Raton Regional Hospital, Jacksonville, Florida, United States of America, Radiation Oncology

Editorial Board Members

  • Meritxell Arenas Prat, MD PhD, Sant Joan University Hospital of Reus, Reus, Spain, Radiation Oncology,  cancer biomarkers,  cancer biology,  dosimetry,  cancer diagnostics
  • Alejandro Berlin, MD, MSc, Princess Margaret Hospital Cancer Centre, Toronto, Canada, Prostate Cancer,  Translational Oncology,  Cancer Genomics,  Clinical Trials
  • Jean-Emmanuel Bibault, MD, MSc, PhD, University Paris Cité, Paris, France, radiation oncology,  medical informatics and artificial intelligence,  radiomics,  big data and machine learning in radiation oncology
  • Pierluigi Bonomo, MD, University Hospital Careggi, Firenze, Italy, Head and neck cancer,  Gastrointestinal cancer,  Supportive care,  High-precision radiotherapy,  Translational science
  • Gerben Borst, MD, PhD, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands, primary brain tumors,  brain and spinal cord metastasis
  • Ross Carruthers, University of Glasgow, Glasgow, United Kingdom
  • Supriya Chopra, MD, Homi Bhabha National Institute, Mumbai, India
  • Monique De Jong, MD PhD, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands, Radiation Oncology,  radioimmunotherapy and gene expression profiles to predict response to radiotherapy
  • Andre Dekker, MSc, Maastricht University, Maastricht, Netherlands, Data Science,  Medical Physics,  Medical Informatics,  Radiotherapy,  Lung Cancer
  • Ludwig Dubois, PhD, Maastricht University Medical Centre+ Radiotherapy, Heerlen, Netherlands, Immunotherapy,  Hypoxia imaging and targeting and Radiation-induced normal tissue toxicity
  • Dan Duda, DMD, PhD, Massachusetts General Hospital, Boston, United States of America, tumour biology,  liver cancer research,  cellular and molecular mechanisms of local and metastatic tumour progression and treatment resistance
  • Emmanouil Fokas, MD, PhD, Frankfurt University of Applied Sciences, Frankfurt am Main, Germany, Radiation Oncology,  Gastrointestinal Malignancies,  Radiobiology,  Translational Research,  High-Precision Radiotherapy
  • Steven J. Frank, MD, The University of Texas MD Anderson Cancer Center, Houston, United States of America, radiation oncology,  proton therapy for head and neck cancer,  prostate brachytherapy,  advanced technologies in Radiation Oncology,  Intensity-Modulated Proton Therapy,  oropharyngeal cancer,  prostate cancer
  • Maria Gambacorta, MD, University Hospital Agostino Gemelli, Rome, Italy, Rectal Cancer,  Gynecological cancer
  • Cihan Gani, MD, University of Tübingen, Tübingen, Germany, Radiation oncology,  radiotherapy,  stereotactic radiosurgery,  radiobiology,  lung cancer. esophageal cancer,  rectal cancer,  precision cancer,  organ preservation
  • Morten Høyer, MD, PhD, Aarhus University Hospital, Aarhus, Denmark, Proton therapy,  neuro-oncology,  uro-oncology,  radiotherapy of children and adolescents,  radiobiology,  clinical trials and translational research. Radiation induced morbidity. Radiobiology,  including proton-RBE and combined immunoradiotherapy
  • Anna Kirby, MD, Royal Marsden NHS Foundation Trust, London, United Kingdom, Breast cancer and radiotherapy
  • Pedro C. Lara, MD, Dr Negrin University Hospital of Gran Canaria, Department of Radiation Oncology, Las Palmas de Gran Canaria, Spain, Radiation Oncology,  Radiotherapy,  Stereotactic body radiation therapy,  brachytherapy
  • Pernille Lassen, MD, PhD, Aarhus University, Aarhus, Denmark, Head and neck cancer,  HPV,  Non-melanoma skin cancer
  • Cécile Le Péchoux, MD, Gustave Roussy, Villejuif, France, lung cancer,  mesothelioma,  radiation oncology,  stereotactic radiosurgery,  dose fractionation
  • Laure Marignol, MSc, PhD, Trinity College Dublin School of Medicine, Dublin, Ireland, Urological cancer,  Hypoxia,  Biomarkers,  Radiation resistance prediction
  • Brian O'Sullivan, MB Bch BAO, FRCPC, Princess Margaret Hospital Cancer Centre, Toronto, Canada, Radiation oncology,  Treatment of locoregional head and neck squamous carcinoma,  Soft tissue sarcoma of the extremities,  Musculoskeletal neoplasia
  • Ian Pereira, MD BASc (Engineering Science), Queen's University, Kingston, Canada, Radiation Oncology,  Stereotactic Radiosurgery
  • Paul Martin Putora, PhD, Saint Gallen Cantonal Hospital, St Gallen, Switzerland, Thoracic oncology,  Urogenital oncology,  Medical informatics,  Decision-making,  Breast cancer
  • Maximilian Schmid, MD, Medical University of Vienna, Wien, Austria, radiotherapy,  soft-tissue sarcoma,  proton therapy,  brachytherapy
  • Esther Troost, MD, PhD, Dresden University Hospital, Dresden, Germany, radiation oncology,  imaged-guided high-precision radiotherapy
  • Guopei Zhu, MD, Shanghai Jiao Tong University, Shanghai, China, radiation oncology,  radiation physics,  stereotactic radiosurgery,  radiation biology,  IMRT

Editorial Office

  • Joe Butler, Stover Court, Bampfylde Street, , EX1 2AH, EX1 2AH, United Kingdom